中性粒细胞/淋巴细胞比值在慢性阻塞性肺疾病急性加重中的研究进展  

Research progress of neutrophil-to-lymphocyte ratio in acute exacerbation of chronic obstructive pulmonary disease

作　　者：杨瑞英 郭岩斐[1] 孙铁英[1] Yang Ruiying;Guo Yanfei;Sun Tieying(Department of Pulmonary and Critical Care Medicine,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing 100730,China)

机构地区：[1]北京医院呼吸与危重症医学科、国家老年医学中心、中国医学科学院老年医学研究所,北京100730

出　　处：《国际呼吸杂志》2024年第9期1102-1106,共5页International Journal of Respiration

基　　金：首都卫生发展科研专项(首发2024-2-4057)。

摘　　要：慢性阻塞性肺疾病是一种异质性肺部病变,表现为持续性、进行性加重的气流受限。在我国,慢性阻塞性肺疾病患病率高,疾病负担重,急性加重是患者的首要死亡因素。目前慢性阻塞性肺疾病急性加重的诊断主要依靠症状的加重,尚缺乏客观有效的生物标志物用以指导诊断和评估。中性粒细胞/淋巴细胞比值作为一种新兴的生物标志物,因其简单便捷、可重复性高的特点,近年来备受关注。本文就中性粒细胞/淋巴细胞比值在慢性阻塞性肺疾病急性加重的风险预测、发病诱因、治疗预后及并发症方面的研究进展作简要综述。Chronic obstructive pulmonary disease(COPD)is a heterogeneous lung condition characterized by persistent and progressive airflow limitation.In China,COPD is severe with a high prevalence and huge disease burden.Acute exacerbation is the leading factor of the mortality among COPD patients.Currently,diagnosis and evaluation of acute exacerbation of COPD(AECOPD)are predominantly determined by symptomatic exacerbation.Objective and effective biomarkers for guiding the diagnosis and assessment of AECOPD are scant.Neutrophil-to-lymphocyte ratio(NLR)has been well concerned as an emerging biomarker for AECOPD due to its simplicity,convenience and high reproducibility.This article briefly reviewed the research progress of NLR in the risk prediction,cause of inducement,treatment,prognosis and complications associated with AECOPD.

关 键 词：肺疾病 慢性阻塞性 中性粒细胞/淋巴细胞比值 急性加重 

分 类 号：R563.9[医药卫生—呼吸系统]